Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to better understand the main barriers to earlier diagnosis and better management of MASLD/MASH patients and to understand the key barriers to adoption of guidelines. This study is a cross-sectional design, conducted across 5 countries in Europe- France, Germany, Spain, United Kingdom (UK), Italy. Study participants, Hepatologists and other metabolically focused healthcare providers (HCPs), will be recruited to complete a 15 minute self-administered online survey.

Official Title
-----------------
Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey

Conditions
-----------------
Non-alcoholic Steatohepatitis (MASH), Non-alcoholic Fatty Liver Disease (MASLD)

Intervention / Treatment
-----------------
* Other: No treatment given


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: For Hepatologists: Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). Male or female, age above or equal to 18 years at the time of signing informed consent. Is a physician Lives in UK, France, Germany, Italy or Spain Primary medical specialty is: 5.a. Hepatology or 5.b. Gastroenterology or Internal Medicine with a subspecialty in Hepatology 6. In practice at least 3 years 7. Spends at least 50 percent of their time in an office/clinic setting 8. Spends at least 60 percent of their time in direct patient care 9. Sees at least 15 patients/month with MASH/MASLD For Metabolically-Focused HCPs (Endocrinologist/General Physician/Family Physician/Internal Medicine): Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). Male or female, age above or equal to 18 years at the time of signing informed consent. Is a physician Lives in UK, France, Germany, Italy or Spain Primary medical specialty is: 5.a. General Physician/Family Practitioner or Endocrinology or 5.b. Internal Medicine without subspecialty in Hepatology 6. In practice at least 3 years 7. Spends less than 50 percent of their time in an office/clinic setting 8. Spends less than 60 percent of their time in direct patient care 9. Sees at least 15 patients/month with suspected/diagnosed MASH/MASLD 10. Sees and actively treats at least 30 patients/month with Type 2 Diabetes (T2D) and/or Obesity Exclusion Criteria: Previous participation in this study. Participation is defined as having given informed consent in this study Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation Does not meet inclusion criteria requirements

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hepatologists<br>Recruited via email through online panel companies with which respondents have provided permission to be contacted for research purposes | Other: No treatment given<br>* No treatment given<br>|
| Metabolically-Focused HCPs<br>Recruited via email through online panel companies with which respondents have provided permission to be contacted for research purposes | Other: No treatment given<br>* No treatment given<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Unaided awareness | Open ended response | At the time of survey response (Day 1) | 
| Aided awareness | Multi- select from defined list | At the time of survey response (Day 1) | 
| Behaviours relative to diagnosing and managing MASLD | Numerical, multi-select from defined list | At the time of survey response (Day 1) | 
| Use of current guidelines | Multi-select from defined list; Likert scales; Numerical Likert scales: 1=Not at all Relevant, 7=Extremely Relevant | At the time of survey response (Day 1) | 
| Barriers in guideline adoption | Multi-select from defined list; Likert scales; Numerical Likert scales: 1=Doesn't impact at all, 7=Greatly impacts | At the time of survey response (Day 1) |